New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
05:59 EDTPFE, AZNAstraZeneca rejects proposal from Pfizer as 'substantially' undervalued
AstraZeneca (AZN) said its board has met and considered the letter from Pfizer (PFE). It stated, "The financial and other terms described in the Proposal are inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer. The large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged. Accordingly, the Board has rejected the Proposal." Leif Johansson, Chairman of AstraZeneca, said: "AstraZeneca continues to invest significantly in research, development and manufacturing in the U.K., Sweden and the U.S. We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the Board believes will deliver significant value for shareholders. Pfizer’s proposal would dramatically dilute AstraZeneca shareholders’ exposure to our unique pipeline and would create risks around its delivery. As such, the Board has no hesitation in rejecting the Proposal." The company added, "Shareholders are strongly advised to take no action."
News For AZN;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 >>
November 16, 2015
13:32 EDTPFECantor helps Moelis clinches advisory role for Pfizer, Reuters reports
Subscribe for More Information
10:27 EDTAZNGoldman puts Conviction Buy-rated Clovis under review
Subscribe for More Information
10:23 EDTAZNClovis price target cut to $28 from $92 at Piper Jaffray
Piper Jaffray analyst Charles Duncan cut his price target for shares of Clovis Oncology (CLVS) to $28 from $92 after the company announced that rociletinib efficacy data matured and the number of patients with a confirmed response is lower than expected. The updated response rate may still ultimately be approvable, but it further hinders rociletinib's competitive positioning compared to AstraZeneca's (AZN) Targrisso, Duncan tells investors in a research note. The analyst pushed back his first rociletinib sales estimate to Q4 of 2016 and lowered the drug's peak penetration of the second line market from 25% to 45%. He reiterates a Neutral rating on Clovis. The stock is down 67%, or $66.93, to $32.50 in morning trading.
09:59 EDTPFEOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
08:32 EDTAZNClovis reopens, down 64% after FDA requests added data for rociletinib
AstraZeneca (AZN), which is at work on a drug similar to rociletinib, is up 2.5% in pre-market trading.
06:33 EDTPFEPfizer, Allergan deal brings focus on U.S. tax-inversion deals, Reuters says
Pfizer's (PFE) takeover bid for Allergan (AGN) has refocused financial markets over a potential move by the U.S. Treasury Department against tax-inversion deals, Reuters reported Friday. The outlook for such a move remained unclear on Friday, the report says. Reference Link
05:57 EDTAZNAstraZeneca urges UK for antibiotics investment shake-up, Financial Time says
AstraZeneca has urged the U.K. government to develop a new model for incentivizing investment in antibiotics, reports the Financial Times. In a letter to the Financial Times, the company said it has joined other "leading voices" in the life sciences sectory to implore Britain to go ahead with a new system rather than waiting for an international agreement. The company said a new payment model was needed that would reward companies' investments but without encouraging the over-use of antibiotics. Reference Link
November 15, 2015
18:13 EDTPFEAllergan, Pfizer targeting late November merger deal, FT says
Subscribe for More Information
November 13, 2015
13:57 EDTPFEAppeals court vacates decision invalidating Medicines Co. Angiomax patents
Subscribe for More Information
11:12 EDTPFEPiper sees Pfizer profiting from Allergan deal, worth $50/share even without one
An acquisition of Allergan (AGN) by Pfizer (PFE) would increase the latter company's profits in 2016-2017 and lift its earnings by a large amount by 2019, wrote research firm Piper Jaffray in a note to investors today. WHAT'S NEW: By 2019, an acquisition of Allergan would increase Pfizer's earnings per share by 13%-16%, estimated Piper analyst Richard Purkiss. The deal would be profitable for Pfizer as early as 2016, the analyst believes. Excluding any acquisition, Pfizer is worth over $50 per share, well above analysts' average price target of $40, Purkiss believes. He kept a $52 price target and Overweight rating on Pfizer. WHAT'S NOTABLE: Yesterday dealReporter, noting that an acquisition of Allergan by Pfizer would be "a giant inversion deal," asserted that the U.S. Treasury could look to take steps to limit or discourage those types of transactions. On November 6, research firm Bernstein said that Allergan's strong results, coupled with the weakness of drug stocks, could cause Allergan to be reluctant to sell itself to Pfizer in the near-term. As a result, the firm thinks that the odds of a deal getting done may be lower than many believe. It kept a $385 price target and Outperform rating on Allergan. PRICE ACTION: In late morning trading, Pfizer rose fractionally to $33.47 and Allergan added 1.3% to $303.87.
09:37 EDTAZNClovis down 3% after FDA approves AstraZeneca lung cancer drug
Subscribe for More Information
09:34 EDTAZNFDA approves Roche's cobas EGFR Mutation Test
Subscribe for More Information
09:31 EDTAZNFDA approves AstraZeneca non-small cell lung cancer treatment
Subscribe for More Information
06:54 EDTPFEPiper sees Pfizer worth over $50/share on standalone basis
Subscribe for More Information
November 12, 2015
13:45 EDTPFEPfizer, Allergan talks could set off further Treasury action, dealReporter says
Subscribe for More Information
November 11, 2015
07:56 EDTPFEBoston Biotech Conferences to hold a conference
Subscribe for More Information
November 10, 2015
18:40 EDTPFEAllergan CEO says some peers 'deserve' pricing scrutiny, Bloomberg reports
In a Bloomberg TV interview Tuesday, Allergan (AGN) CEO Brent Saunders said certain drugmakers "deserve" recent scrutiny over drug price hikes. "There are a few companies that were very aggressive and perhaps took it too far, and deserve the attention they are getting. I think it's good. Transparency helps solve some of these issues," said the CEO. Asked whether he would be interested in acquiring embattled Valeant (VRX), Saunders said, "The things we look to buy are really first-in-class drugs, growth assets. There are a few of those in Valeant but there are also a lot of older medicines." Other companies that have received attention on the issue include Retrophin (RTRX), Pfizer's (PFE) Hospira, and Mallinckrodt (MNK). Reference Link
17:34 EDTPFEPfizer, Allergan considering Saunders as CEO of combined company, Bloomberg says
Subscribe for More Information
06:21 EDTAZNDr. Reddy's Labs aware of TRO passed by Court for generic esomeprazole product
Subscribe for More Information
06:03 EDTAZNPiper sees Biotech fundamentals as 'strong' despite pricing chatter
Subscribe for More Information
1 | 2 | 3 | 4 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use